Chemokines and NSCLC: Emerging role in prognosis, heterogeneity, and therapeutics
Authors:
- 3 July 2022
- journal article
- research article
- Published by Elsevier in Seminars in Cancer Biology
- Vol. 86 (Pt 2) , 233-246
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health
- U.S. Department of War (W81XWH-16–1-0641, W81XWH-20–1-0362, W81XWH-22–1-0331)
This publication has 206 references indexed in Scilit:
- Vascular Endothelial Growth Factor Induces CXCL1 Chemokine Release via JNK and PI-3K-Dependent Pathways in Human Lung Carcinoma Epithelial CellsInternational Journal of Molecular Sciences, 2013
- A CXCL1 Paracrine Network Links Cancer Chemoresistance and MetastasisCell, 2012
- Oncogenic KRAS‐induced interleukin‐8 overexpression promotes cell growth and migration and contributes to aggressive phenotypes of non‐small cell lung cancerInternational Journal of Cancer, 2011
- Re-expression of CXCL14, a common target for epigenetic silencing in lung cancer, induces tumor necrosisOncogene, 2010
- Chemokines and chemokine receptors: new insights into cancer-related inflammationTrends in Molecular Medicine, 2010
- Tumor Self-Seeding by Circulating Cancer CellsCell, 2009
- The Nuclear Factor NF- B Pathway in InflammationCold Spring Harbor Perspectives in Biology, 2009
- THE CHEMOKINE CXCL16 IS HIGHLY AND CONSTITUTIVELY EXPRESSED BY HUMAN BRONCHIAL EPITHELIAL CELLSExperimental Lung Research, 2009
- CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculatureProceedings of the National Academy of Sciences, 2007
- Inflammation and cancerNature, 2002